98%
921
2 minutes
20
High B-type natriuretic peptide (BNP) levels are associated with new atrial fibrillation (AF). This study investigated the distribution of AF detection rates according to BNP levels in patients with cryptogenic stroke (CS) using an insertable cardiac monitor (ICM). We enrolled consecutive patients with CS who underwent ICM implantation between October 2016 and September 2020 at eight stroke centers in Japan. Those with BNP levels were divided into three groups by tertiles. We evaluated the association of BNP levels with AF detection. Youden's index was calculated to identify the optimal cutoff for BNP. Of 417 patients, we analyzed 266 patients with BNP data. The tertile range of BNP level was 19.0 to 48.5 pg/mL. AF detection rate was 13.3%/year, 12.8%/year, and 53.7%/year in the low-BNP (≤19.0), mid-BNP (19.1-48.4), and high-BNP (≥48.5) groups, respectively (log-rank trend < 0.01). Compared with low-BNP group, the adjusted hazard ratios for AF detection in mid-and high-BNP groups were 0.91 [95% confidence interval (CI) 0.46-1.78] and 2.17 (95% CI 1.14-4.13), respectively. Receiver operating characteristic curve analysis showed the optimal cutoff value was 43.4 pg/mL. The area under curve using BNP to predict AF detection was 0.69. The BNP level was associated with AF detection in patients with CS. This relationship changed around the BNP levels of 40-50 pg/mL.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11445933 | PMC |
http://dx.doi.org/10.3389/fneur.2024.1436062 | DOI Listing |
Heart Lung
September 2025
Department of Cardiology, School of Medicine, Mugla Sitki Kocman University, Mugla, Turkey. Electronic address:
Background: Acute heart failure with reduced ejection fraction (AHF) remains a leading cause of ED visits, hospitalizations, and in-hospital mortality.
Objectives: To evaluate the prognostic utility of the Scottish Inflammatory Prognostic Score (SIPS) in patients with AHF.
Methods: This retrospective study analyzed 508 patients admitted with AHF between November 2022 and November 2024.
Introduction: Androgen receptor signaling inhibitors (ARSIs) improve survival in prostate cancer; however, it may increase cardiovascular risks, especially in elderly patients with heart disease.
Case Presentation: A 94-year-old man with aortic valve stenosis, hypertension, and diabetes had a nodal metastatic progression of prostate cancer at 88 years of age, leading to the implementation of androgen deprivation therapy (ADT). After 5 years of therapy, prostate-specific antigen (PSA) re-elevated; however, ADT was maintained.
Hypertens Res
September 2025
Department of Cardiovascular Medicine, Nippon Medical School, Tokyo, Japan.
Mitochondria are dynamic organelles that can change their morphology. The role of these mitochondrial dynamics in cardiomyocytes remains obscure in patients with heart failure (HF). Endomyocardial biopsies were performed consecutively in 127 HF patients, and mitochondrial morphology data were obtained from 111 patients by electron microscopy.
View Article and Find Full Text PDFAging Dis
August 2025
Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China.
Stroke-heart syndrome (SHS) is associated with early mortality in patients with acute ischemic stroke (AIS). However, reliable methods for timely risk stratification remain elusive. Combined monitoring of neurohormonal activation and electrocardiography may help identifying early mortality risk in SHS patients.
View Article and Find Full Text PDFBMC Cardiovasc Disord
September 2025
Department of Preventive Cardiology, National Cerebral and Cardiovascular Center, 6-1, Kishibe-Shinmachi, Suita, Osaka, 564-8565, Japan.
Background: Increased plasma levels of B-type natriuretic peptide (BNP) serve as a biomarker for heart failure (HF). This study aimed to develop a risk score to predict elevated BNP levels using traditional cardiovascular disease (CVD) risk factors.
Methods And Results: We analyzed data from 2809 Japanese individuals aged ≥ 40 years from the Suita Study, a population-based prospective cohort.